Bionano Genomics Inc. (NASDAQ:BNGO) has a beta value of 2.26 and has seen 7.53 million shares traded in the last trading session. The company, currently valued at $529.63M, closed the last trade at $1.92 per share which meant it gained $0.09 on the day or 4.92% during that session. The BNGO stock price is -126.56% off its 52-week high price of $4.35 and 39.58% above the 52-week low of $1.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.19 million shares traded. The 3-month trading volume is 7.72 million shares.
The consensus among analysts is that Bionano Genomics Inc. (BNGO) is a Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.11.
Bionano Genomics Inc. (NASDAQ:BNGO) trade information
Sporting 4.92% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the BNGO stock price touched $1.92 or saw a rise of 3.03%. Year-to-date, Bionano Genomics Inc. shares have moved 31.51%, while the 5-day performance has seen it change 6.08%. Over the past 30 days, the shares of Bionano Genomics Inc. (NASDAQ:BNGO) have changed 16.36%. Short interest in the company has seen 46.73 million shares shorted with days to cover at 8.15.
Wall Street analysts have a consensus price target for the stock at $6.70, which means that the shares’ value could jump 71.34% from current levels. The projected low price target is $3.50 while the price target rests at a high of $12.00. In that case, then, we find that the current price level is -525.0% off the targeted high while a plunge would see the stock gain -82.29% from current levels.
Bionano Genomics Inc. (BNGO) estimates and forecasts
Figures show that Bionano Genomics Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 5.49% over the past 6 months, with this year growth rate of -50.00%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -57.10% and -37.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 46.90%.
3 analysts offering their estimates for the company have set an average revenue estimate of $6.79 million for the current quarter. 3 have an estimated revenue figure of $7.25 million for the next quarter concluding in Dec 2022. Year-ago sales stood $4.23 million and $6.3 million respectively for this quarter and the next, and analysts expect sales will grow by 60.50% for the current quarter and 15.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 33.30% over the past 5 years.
Bionano Genomics Inc. is expected to release its next earnings report between February 27 and March 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bionano Genomics Inc. (NASDAQ:BNGO)’s Major holders
Insiders own 1.91% of the company shares, while shares held by institutions stand at 28.86% with a share float percentage of 29.42%. Investors are also buoyed by the number of investors in a company, with Bionano Genomics Inc. having a total of 211 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 21.02 million shares worth more than $29.01 million. As of Jun 29, 2022, Blackrock Inc. held 7.26% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 15.63 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $21.58 million and represent 5.40% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Jun 29, 2022, the former fund manager holds about 3.04% shares in the company for having 8.82 million shares of worth $12.17 million while later fund manager owns 6.27 million shares of worth $11.47 million as of Sep 29, 2022, which makes it owner of about 2.16% of company’s outstanding stock.